This Article Full Text (PDF) All Versions of this Article: 0269881108093841v1 23/4/410    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Jasinski, D. Articles by Krishnan, S Search for Related Content PubMed PubMed Citation Articles by Jasinski, D. Articles by Krishnan, S Social Bookmarking                         What's this?

Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers

Department of Medicine, Johns Hopkins University, Baltimore, MD, USA

S Krishnan

Formerly of New River Pharmaceuticals Inc., Belvedere, CA, USA

Abstract

The objective of this study is to determine the safety, tolerability and abuse liability of single intravenous (i.v.) doses of lisdexamfetamine dimesylate (LDX) and immediate-release d-amphetamine sulphate in adult stimulant abusers compared with placebo. Adult substance abusers were enrolled in this phase I, randomized, single-centre, double-blind study. An initial cohort of three subjects was enrolled to assess safety followed by a primary cohort that consisted of nine subjects. Single i.v. doses of LDX (25 or 50 mg), immediate-release d-amphetamine sulphate (10 or 20 mg) or placebo were administered at a minimum of 48-h intervals in a single-dose, three-way crossover design. 20 mg of d-amphetamine showed significantly increased abuse-related liking scores compared with placebo (P < 0.05), whereas the liking effects of 50 mg LDX did not significantly differ from placebo. The mean C_max of d-amphetamine was 38.9 ± 8.1 and 105 ± 91.4 ng/ml after the administration of 50 mg LDX and 20 mg d-amphetamine respectively. The mean T_max of d-amphetamine was 2.51 h after the administration of 50 mg LDX and 0.82 h after the administration of 20 mg d-amphetamine. LDX was well tolerated in this population. In contrast to d-amphetamine, LDX administered intravenously did not produce significant subjective abuse-related liking scores at assessed doses.

Key Words: abuse • ADHD • LDX • stimulant • Vyvanse

This version was published on June 1, 2009

Journal of Psychopharmacology, Vol. 23, No. 4, 410-418 (2009)
DOI: 10.1177/0269881108093841


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. Popovic, P. Bhattacharya, and L. Sivaswamy Lisdexamfetamine: A prodrug for the treatment of attention-deficit/hyperactivity disorder Am. J. Health Syst. Pharm., November 15, 2009; 66(22): 2005 - 2012. [Abstract] [Full Text] [PDF]

				S. S. Negus, M. H. Baumann, R. B. Rothman, N. K. Mello, and B. E. Blough Selective Suppression of Cocaine- versus Food-Maintained Responding by Monoamine Releasers in Rhesus Monkeys: Benzylpiperazine, (+)Phenmetrazine, and 4-Benzylpiperidine J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 272 - 281. [Abstract] [Full Text] [PDF]

				B. J Cowles Lisdexamfetamine for Treatment of Attention-Deficit/Hyperactivity Disorder Ann. Pharmacother., April 1, 2009; 43(4): 669 - 676. [Abstract] [Full Text] [PDF]